SGLT2 inhibitors, including dapagliflozin, are established treatments for patients with type 2 diabetes leading to improved glucose control as well as decreased risk of cardiovascular events and development of kidney disease (1, 2, 3, 4, 5, 6, 7). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.